drugset
drugset / Trial / NCT05577442

Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer

NCT05577442 ↗

Phase 2 Unknown 52 enrolled Peking University Cancer Hospital & Institute
NaSingle-groupOpen-labelTreatment

Summary

This study investigates the efficacy and safety of trastuzumab, pyrotinib combined with dalpiciclib and endocrine therapy for patients with advanced HR+/HER2+ brest cancer, providing more possible effective regimens for the survival benefit of these patients in clinical practice.

Timeline

Start
2022-10-20
Primary completion
2023-10-20
Completion
2024-10-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalpiciclib Small molecule 125 mg —
Subject Pyrotinib Small molecule 320 mg —
Subject Trastuzumab Monoclonal antibody 6 mg —

Indications

breast neoplasm